To study the frequency of T790M mutations in advanced EGFR-mutant lung adenocarcinoma patients with acquired resistance after first-line EGFR-TKI treatment, Huang et al. [35] enrolled 205 EGFR-mutant stage IIIB-IV lung adenocarcinoma patients. Here, EGFR is linked to lung adenocarcinoma.